Anne Osdoit is a Partner at Sofinnova Partners. She joined the firm in 2019 following several years as a Venture Partner for Sofinnova.
Anne is a member of the Sofinnova MD Start Fund, which specializes in early-stage medical devices. MD Start is Sofinnova’s in-house medtech accelerator led by a team of operational experts who work with physicians and inventors to build companies often starting from a very early stage when the project is just an idea or a prototype. As part of the team’s hands-on approach, she has been the Chief Executive Officer of SafeHeal and Ablacare, portfolio companies in the MD Start II Fund, before the leadership was successfully transitioned to a longer-term team. She is also the CEO of Moon Surgical and Gradient Denervation Technologies, two Sofinnova MD Start III portfolio companies.
Prior to joining Sofinnova, Anne helped develop Mauna Kea Technologies, a Paris-based medical technology company with global presence, developing a disruptive “optical biopsy” technology. Over the course of a decade, Anne held various positions of increasing responsibility in clinical and regulatory development as well as marketing and sales. She was also closely involved in multiple financing rounds, including the company’s initial public offering on the Paris Euronext, a highly successful operation and the largest public listing for the sector that year.
Anne is an independent board member of FeetMe and Cardiologs Technologies, two Paris-based startups in e-health and connected medical devices in the fields of neurodegenerative diseases and cardiology.
Anne is a trained biomedical engineer from Ecole Polytechnique of Paris, France and Johns Hopkins University in Baltimore, US. She holds additional degrees in Biostatistics and epidemiology applied to clinical trials (Université Pierre et Marie Curie), as well as Corporate Finance (London School of Economics).